Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Canaccord

<< Previous

Bullboard Posts

Next >>

Comment by filmguyTorontoon Feb 18, 2021 4:55pm

178 Views

Post# 32604556

RE:RE:RE:RE:Canaccord

Unfortunately, this dilutes all of the shares we all own. So, it's a temporary drop. But, it will create more discussion and interest for Antibe. So, a good thing overall. From somehting I read earlier, they need something like $300 Million to complete the Phase 3 trials. They just received $100 million from the China Deal, plus an additonal $35Million from this deal. Moving to the OTC Market was a good sign. Once theyure on the Nasdaq, it should pop and help solidafy a deal with Bayer, who are waiting in the shadows. I also read, they may sel ltheir Vetranarian Division in order to raise the remainig money for the phase 3 trials. Its going to be a long haul.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages